Thyroid and renal disorder occurrences were correlated with anti-PD-1, and incidences of IRR, hepatobiliary disorders and pyrexia (or chills) were more correlated with anti-PD-L1 therapy. Here, PDCD1 is linked to hepatobiliary disorder.